Evaluation of Warfarin Drug Interaction Listings in US Product Information for Warfarin and Interacting Drugs

Clinical Therapeutics

Volumn 33, Issue 1, 2011, Pages 36-45

  Hines, Lisa E ^a   Ceron Cabrera, Diana ^b   Romero, Klaus ^c   Anthony, Marietta ^d   Woosley, Raymond L ^c   Armstrong, Edward P ^a   Malone, Daniel C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSIDAD LA SALLE   (Mexico)

^c CRITICAL PATH INSTITUTE   (United States)

^d Critical Path Institute   (United States)

Author keywords

Adverse drug event; Drug interaction; Food and Drug Administration; Product labeling; Warfarin

Indexed keywords

ALCOHOL; ALLOPURINOL; AMIODARONE; AZATHIOPRINE; CARBAMAZEPINE; CEFAZOLIN; CHLORAMPHENICOL; CIMETIDINE; DICLOXACILLIN; DISULFIRAM; ETACRYNIC ACID; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; FLUOXETINE; FLUTAMIDE; FLUVOXAMINE; GEMFIBROZIL; GENERIC DRUG; GLUCAGON; GRISEOFULVIN; HEPARIN; INFLUENZA VACCINE; METHYLPHENIDATE; METRONIDAZOLE; MEVINOLIN; MICONAZOLE; PARACETAMOL; UNINDEXED DRUG; WARFARIN;

ARTICLE; DRUG INFORMATION; DRUG INTERACTION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; UNITED STATES;

ANTICOAGULANTS; DRUG INTERACTIONS; DRUG LABELING; DRUGS, GENERIC; HUMANS; TERMINOLOGY AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 79952495577     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.021     Document Type: Article

References (24)

1. Howard P.A., Ellerbeck E.F., Engelman K.K., Patterson K.L. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002, 11:569-576.
2. Kotirum S., Chaiyakunapruk N., Jampachaisri K., et al. Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy. Pharmacoepidemiol Drug Saf 2007, 16:216-222.
3. Snaith A., Pugh L., Simpson C.R., McLay J.S. The potential for interaction between warfarin and coprescribed medication: A retrospective study in primary care. Am J Cardiovasc Drugs 2008, 8:207-212.
4. Verhovsek M., Motlagh B., Crowther M.A., et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review. BMC Geriatr 2008, 8:13.
5. Wittkowsky A.K., Boccuzzi S.J., Wogen J., et al. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004, 24:1668-1674.
6. Gurwitz J.H., Field T.S., Radford M.J., et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007, 120:539-544.
7. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl 6):160S-198S. American College of Chest Physicians.
8. Holbrook A.M., Pereira J.A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.
9. Abarca J., Malone D.C., Armstrong E.P., et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003) 2004, 44:136-141.
10. Chao S.D., Maibach H.I. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 2005, 6:105-111.
11. Fulda T.R., Valuck R.J., Vander Zanden J., et al. Disagreement among drug compendia on inclusion and ratings of drug-drug interaction. Curr Ther Res 2000, 61:540-548. US Pharmacopeia Drug Utilization Review Advisory Panel.
12. Olvey E.L., Clauschee S., Malone D.C. Comparison of critical drug-drug interaction listings: The Department of Veterans Affairs medical system and standard reference compendia [published correction appears in Clin Pharmacol Ther. 2010;88:138]. Clin Pharmacol Ther 2010, 87:48-51.
13. Trifirò G., Corrao S., Alacqua M., et al. Interaction risk with proton pump inhibitors in general practice: Significant disagreement between different drug-related information sources. Br J Clin Pharmacol 2006, 62:582-590. UVEC Group.
14. Vitry A.I. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007, 63:709-714.
15. Wong C.M., Ko Y., Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: Profiling and comparison of two drug compendia. Ann Pharmacother 2008, 42:1737-1748.
16. Anthony M., Romero K., Malone D.C., et al. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 2009, 86:425-429.
17. Bergk V., Haefeli W.E., Gasse C., et al. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: A comparison with evidence from the literature. Eur J Clin Pharmacol 2005, 61:327-335.
18. Wang L.M., Wong M., Lightwood J.M., Cheng C.M. Black box warning contraindicated comedications: Concordance among three major drug interaction screening programs. Ann Pharmacother 2010, 44:28-34.
19. New Requirements for Prescribing Information US Food and Drug Administration (FDA), Accessed November 1, 2010. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm.
20. Coumadin [prescribing information] August 2007, Bristol-Myers Squibb Company, Princeton, NJ.
21. Fleiss J.L. Measuring nominal scale agreement among many raters. Psychol Bull 1971, 76:378-382.
22. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
23. Gabb G.M. Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug. Med J Aust 1996, 164:700-701.
24. Drugs@FDA. FDA Approved Drug Products US Food and Drug Administration (FDA), Accessed November 1, 2010. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/.